Pediatric Neurology
Volume 31, Issue 1 , Pages 73-75 , July 2004

Hair analysis differentiates chronic from acute carbamazepine intoxication

  • Evangelia C. Mantzouranis, MD

      Affiliations

    • Department of Pediatrics, University Hospital of Heraklion, Heraklion, Crete, Greece
    • School of Medicine, University of Crete, Heraklion, Greece
    • Corresponding Author InformationCommunications should be addressed to:Dr. Mantzouranis; Department of Pediatrics; University Hospital of Heraklion; PO Box 1352; Heraklion 71110, Crete; Greece
    • ,
  • George K. Bertsias, MD

      Affiliations

    • School of Medicine, University of Crete, Heraklion, Greece
    • Laboratory of Toxicology, University of Crete, Heraklion, Greece
    • ,
  • Eleftherios G. Pallis, MD

      Affiliations

    • School of Medicine, University of Crete, Heraklion, Greece
    • Laboratory of Toxicology, University of Crete, Heraklion, Greece
    • ,
  • Aristidis M. Tsatsakis, PhD

      Affiliations

    • School of Medicine, University of Crete, Heraklion, Greece
    • Laboratory of Toxicology, University of Crete, Heraklion, Greece

Received 20 August 2003 ,Accepted 29 December 2003.

References 

  1. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. Clin Pharmacokinet. 1986;11:177–198
  2. Warner A, Priviteza M, Bates D. Standards of laboratory practice (Antiepileptic drug monitoring). Clin Chem. 1998;44:1085–1095
  3. Tsatsakis AM, Tzatzarakis M. Sectional hair testing (Judicial and clinical applications). Pure Appl Chem. 2000;72:1057–1066
  4. Psillakis T, Tsatsakis AM, Christodoulou P, Michalodimitrakis M, Paritsis N, Helidonis E. Carbamazepine levels in head hair of patients under long-term treatment (A method to evaluate the history of drug use). J Clin Pharm. 1999;39:55–67
  5. Montgomery VL, Richman BJ, Goldsmith LJ, Rodgers GC. Severity and carbamazepine level at time of initial poison center contact correlate with outcome in carbamazepine poisoning. J Toxicol Clin Toxicol. 1995;33:311–323
  6. Delgado Iribarnegaray MF, Santo Bueldga D, Garcia Sanchez MJ, Otero MJ, Falcao AC, Dominquez-Gil A. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit. 1997;19:132–139
  7. Schmidt S, Schmitz-Buhl M. Signs and symptoms of carbamazepine overdose. J Neurol. 1995;242:169–173
  8. Weaver DF, Camfield P, Fraser A. Massive carbamazepine overdose (Clinical and pharmacologic observations in five episodes). Neurology. 1988;38:755–759
  9. Evans WE, Relling MV. Pharmacogenomics (Translating functional genomics into rational therapeutics). Science. 1999;286:487–491
  10. Pearce RE, Vakkalagadda GR, Leeder JS. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos. 2002;30:1170–1179
  11. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta. 2002;315:137–155
  12. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271–1294
  13. Williams J, Patsalos PN, Mei Z, Schapel G, Wilson JF, Richens A. Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit. 2001;23:15–20
  14. Eichelbaum M, Kroemer HK, Mikus G. Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett. 1992;64-65:115–122

PII: S0887-8994(04)00051-7

doi: 10.1016/j.pediatrneurol.2003.12.017

Pediatric Neurology
Volume 31, Issue 1 , Pages 73-75 , July 2004

Article Tools

* Image Usage & Resolution